Oncology

Latest News

Highlights From ASCO 2024

ICYMI: Highlights From ASCO 2024

By Pearl Steinzor

December 21st 2024

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

chemotherapy | Image credit: Penn Medicine

The High Cost of Shortages of Low-Cost Chemotherapy

By Interview by Mary Caffrey

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

By Pearl Steinzor

December 17th 2024

FDA approved stamp in black with a red ribbon across it | Image credit: BHM - stock.adobe.com

Cosibelimab Approved for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

December 16th 2024

Highlights From COA 2024

ICYMI: Highlights From COA 2024

By Pearl Steinzor

December 14th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

February 22nd 2013

FDA Approves New Treatment for Late-Stage Breast Cancer

February 19th 2013

Cancer Rehab Begins To Bridge A Gap For Patients

February 18th 2013

The Growing Cost of Specialty Pharmacy-Is it Sustainable?

We only have to take a brief look back to see that 10 years ago, most specialty drugs were injectable agents used to treat conditions such as rheumatoid arthritis, multiple sclerosis, and growth disorders. Today, the list of agents that is considered specialty includes many oral drugs and even some inhaled agents. In just more than 2 decades, the specialty drug market place has grown substantially.

February 13th 2013

Short-Term Costs Associated With Primary Prophylactic G-CSF Use During Chemotherapy

Suja S. Rajan, MHA, MS, PhD William R. Carpenter, MHA, PhD Sally C. Stearns, PhD Gary H. Lyman, MD, MPH

Granulocyte colony-stimulating factor therapy reduces hospitalizations and improves chemotherapy administration in elderly breast cancer patients, but increases overall Medicare costs during first year of therapy.

January 30th 2013

Abraxane Capitalizes on the Resurgence of Chemotherapy Combinations in Pancreatic Cancer at ASCO GI 2013

January 29th 2013

Less is More? New Study Indicates Less Invasive Treatment May Yield Better Results for Breast Cancer Patients

Bruce Feinberg, DO, Speaks About Clinical Pathways in Oncology Care

January 24th 2013

Bruce Feinberg, DO, Speaks About Clinical Pathways in Oncology Care

Bruce Feinberg, DO, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, says that there is a tremendous amount of waste in the system.

Darius Lakdawalla, PhD, Discusses the Payer/Provider Relationship in Oncology Management

January 22nd 2013

Darius Lakdawalla, PhD, Discusses the Payer/Provider Relationship in Oncology Management

Darius Lakdawalla, PhD, Director of Research, Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, thinks that payers follow the lead of providers in oncology management.

January 21st 2013

Revisiting the Integrated Delivery Network Model

The idea behind an integrated delivery network (IDN)-a concept that was developed in the 1980s and widely implemented in the 1990s-is that a network of facilities and providers can work together to offer a continuum of care in a particular geographic area. Although the concept was one that initially drew praise, the implementation of this type of system did not gain momentum from the onset. However, as time has elapsed, advancements have made this model worth revisiting.

January 21st 2013

New Pump a 'Game-Changer' for Cancer Patients

January 16th 2013

500,000 Women to be Offered Breast Cancer Drugs

Jan Berger, MD, MJ, Addresses Challenges in Oncology Management

January 15th 2013

Jan Berger, MD, MJ, Addresses Challenges in Oncology Management

"Oncology is a very emotional area," says Jan Berger, MD, MJ, President & CEO, Health Intelligence Partners, Editor-in-Chief, The American Journal of Pharmacy Benefits.

January 10th 2013

Pap Test For Ovarian Cancer, Coming Soon?

Robert Gamble Talks about the Challenges Payers and Providers Face in Oncology Management

January 2nd 2013

Robert Gamble Talks about the Challenges Payers and Providers Face in Oncology Management

In this video, Robert Bo Gamble, Director, Strategic Practice Initiatives, Community Oncology Alliance, Washington, DC, says that it is critical for payers and providers to come together in oncology management.

January 2nd 2013

Expert Roundtable Panel Discussion: The Future of Payer Management of Oncology

December 31st 2012

December 31st 2012

Oncology, Innovation, and Healthcare

This article is based on the keynote address by Clifford Goodman, PhD

December 31st 2012

Developing Comparative Effectiveness Research in Oncology

This article is based on the presentation by Jeffrey D. Dunn, PharmD, MBA

December 31st 2012

Practical Application of Clinical Pathways

This article is based on the presentation by Bruce A. Feinberg, DO

December 31st 2012

Quality Measures in Oncology

This article is based on the presentation by Ira M. Klein, MD, MBA, FACP

December 31st 2012

Innovative Payment Models in Oncology Care

This article is based on the presentation by Peter B. Bach, MD, MAPP

December 31st 2012

Data Tracking and Point of Service Decision Support

This article is based on the presentation by Andrew L. Pecora, MD, FACP, CPE

December 31st 2012

Healthcare, the National Debt, and Taxes

This article is based on the presentation by Michael E. Chernew, PhD

Richard T. Hoppe, MD, Discusses the Current Role and Utility of Radiation Therapy

December 9th 2012

Richard T. Hoppe, MD, Discusses the Current Role and Utility of Radiation Therapy

Richard T. Hoppe, MD, Professor of Radiation Oncology - Radiation Therapy, Stanford School of Medicine, discussed the current role and utility of radiation therapy in patients with early stage Hodgkins Lymphoma when compared to conventional chemotherapy.

December 6th 2012

Bigger Role Seen for Breast Cancer Drug

November 30th 2012

Appendix A -- Value of Survival Gains in Chronic Myeloid Leukemia

November 30th 2012

Dynamic Cost-Effectiveness of Oncology Drugs

Yang Lu, PhD John R. Penrod, PhD Neeraj Sood, PhD Saarah Woodby, BA Tomas Philipson, PhD

November 30th 2012

Value of Survival Gains in Chronic Myeloid Leukemia

Wesley Yin, PhD John R. Penrod, PhD J. Ross Maclean, MD Darius N. Lakdawalla, PhD Tomas Philipson, PhD

Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.

November 21st 2012

Payer Management of Oncology: An In-Depth Look

On Friday, November 16, The American Journal of Managed Care hosted its first annual live meeting, "Translating Evidence-Based Research into Value-Based Decisions in Oncology." The conference, which brought together stakeholders from all sides of the managed care industry, provided an arena for healthcare professionals to discuss new, innovative payment models being utilized by both payers and providers.

November 20th 2012

Utilization of HER2 Genetic Testing in a Multi-Institutional Observational Study

Katrina A.B. Goddard, PhD Erin J. Aiello Bowles, MPH Heather Spencer Feigelson, PhD, MPH Laurel A. Habel, PhD Sharon Hensley Alford, PhD Catherine A. McCarty, PhD, MPH Larissa Nekhlyudov, MD, MPH Adedayo A. Onitilo, MD, MSCR, FACP Alanna K. Rahm, PhD, MS Jennifer A. Webster, MS

Evaluation of real-world implementation of HER2 testing showed that uptake was high (>90%) and trastuzumab treatment was targeted to patients with positive HER2 status.

...

170 171 172 173 174 175 176 177 178

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions